Venetoclax for multiple myeloma - mechanism of action and next steps

Venetoclax for multiple myeloma - mechanism of action and next steps

VJHemOnc

3 years
578 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the mechanism of action of venetoclax and next steps for the drug in multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2 and has recently been approved for the treatment of chronic lymphocytic leukemia (CLL). According to Prof Boise, only a small fraction of multiple myeloma patients appear to be sensitive to venetoclax and the next step is to find a marker that can identify those patients. Another area of research concerns drug combinations, i.e. finding drugs such as dexamethasone, that can be combined with venetoclax. Recorded at the Myeloma 2016 meeting held in Boston, MA.
Up Next Autoplay
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
1 Views
Cancer-News 23 minutes
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
5 Views
kidneycancer 18 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
4 Views
kidneycancer 20 hours
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
3 Views
CURC 22 hours
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 22 hours
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 23 hours
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 2 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 2 days